Infectious Diseases

ACTT-4 Trial Summary: Baricitinib in Covid-19

2022 ACTT-4 TRIAL Baricitinib versus dexamethasone for adults hospitalised with COVID-19 double-blind, double placebo-controlled, randomised controlled trial M Objective: To compare baricitinib in combination with remdesivir versus dexamethasone with remdesivir at preventing progression to mechanical ventilation or death 1010 patients … Read More

ACTIV-4B Trial Summary: Antithrombotic Therapy in Covid-19

2021 ACTIV-4B TRIAL Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19 minimal-contact, adaptive, randomized, double-blind, placebo-controlled Objective: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but … Read More

ACTIV-3 Trial: Monoclonal Antibody for Covid-19

2020 ACTIV-3 TRIAL Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 Multicenter, open-label, randomized comparative trial M Objective: To assess the efficacy of LY-CoV555, a neutralizing monoclonal antibody in hospitalized Covid-19 patients without end-organ damage. Hospitalized patients with Covid-19 who … Read More

ACTION Trial Summary: Anticoagulation for Hospitalized Covid-19 Patients

2021 ACTION TRIAL: Therapeutic vs. prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer Pragmatic, open-label (with blinded adjudication), multicentre, randomised Objective: to evaluate therapeutic anticoagulation compared with prophylactic anticoagulation among patients admitted with coronavirus disease 2019 … Read More

MICHELLE Trial Summary: Rivaroxaban for Thromboprophylaxis in Covid-19

2022 MICHELLE TRIAL Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 Pragmatic, open-label, multicentre, randomized controlled trial Objective: To investigate if extended thromboprophylaxis with Rivaroxaban after hospitalization due to COVID-19 decrease rates of venous & arterial thromboembolism … Read More

ATESS Trial Summary: Vitamin C + Thiamine for Septic Shock

2020 ATESS TRIAL Combination therapy of vitamin C and thiamine for septic shock Multicentre, double-blind, randomized controlled trial Objective: To evaluate the effects of early combination therapy with intravenous vitamin C and thiamine on recovery from organ failure in patients … Read More

VITAMINS Trial: Vitamin C, hydrocortisone, and thiamine in Septic Shock

2021 2021 VITAMINS TRIAL M Effect of Vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock Open label, multi-centre, randomized, phase IIb clinical trial Objective: To investigate whether … Read More

ANTHARTIC Trial Summary: Prevention of Ventilator-Associated Pneumonia after Cardiac Arrest

2019 ANTHARTIC TRIAL M Prevention of early Ventilator-Associated Pneumonia after cardiac arrest Multicentre, randomised, double-blind, placebo-controlled Objective: To investigate whether in post out-of-hospital cardiac arrest (OOHCA) patients treated with targeted temperature management, does the use of empirical antibiotics prevent early … Read More

ACTION Trial: Anticoagulation in COVID-19

2021 ACTION TRIAL Therapeutic vs. prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer Pragmatic, open-label (with blinded adjudication), multicentre, randomised Objective: to evaluate therapeutic anticoagulation compared with prophylactic anticoagulation among patients admitted with coronavirus disease 2019 … Read More